Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.33 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.33 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.33 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.33 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.33 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.33 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.33 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6127789 | 1.00 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL18595259 | 1.00 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL17037490 | 1.00 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL16383055 | 0.93 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL16383069 | 0.93 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL16766054 | 0.93 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL25907745 | 0.93 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL21948079 | 0.93 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL21948078 | 0.93 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL19043993 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220056037-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-02-24 | — | — | US | disclosed |
| US-9586931-B2 | Triazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | SYK, BTK, TYRO3 | ALDH1A1 3298/4885L3MBTL1 4097/4885ATP1A1 3540/4885 |
| US-20220056037-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | ALDH1A1 4227/4885L3MBTL1 3154/4885ATP1A1 3832/4885 |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | ALDH1A1 4227/4885L3MBTL1 3154/4885ATP1A1 3832/4885 |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | ALDH1A1 4227/4885L3MBTL1 3154/4885ATP1A1 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.